Guardian Pharmacy Reports Strong Q4 & FY25 Results, Raises 2026 Adjusted EBITDA Guidance
GRDN sits 85% above its 52-week low of $18.37 on elevated volume (2.4× avg).
Summary
Guardian Pharmacy Services announced strong Q4 and full-year 2025 financial results, including a significant shift to net income and a raised Adjusted EBITDA guidance for 2026, reflecting robust operational performance.
Key Events · Earnings and Guidance · GRDN
-
Strong Q4 and Full Year 2025 Financial Performance
Reported Q4 2025 revenue of $397.6 million (up 17% YoY) and full-year revenue of $1.45 billion (up 18% YoY), with organic growth of 12% and 13% respectively. Adjusted EBITDA for Q4 grew 53% to $39.5 million, and for the full year, it increased 27% to $115.1 million.
-
Significant Turnaround in Net Income
Achieved a net income of $49.0 million for the full year 2025, a substantial improvement from a net loss of $71.0 million in 2024. Q4 net income was $21.3 million, an 81% increase year-over-year.
-
Raised 2026 Adjusted EBITDA Guidance
The company raised its full-year 2026 Adjusted EBITDA guidance to a range of $120 million – $124 million, up from the previous guidance of $115 million – $118 million, indicating increased confidence in future profitability.
-
Healthy Balance Sheet and Operational Growth
Ended 2025 with $65.6 million in cash and cash equivalents, significantly up from $4.7 million in 2024, and no long-term debt outstanding under its $75 million credit facility. The company also expanded its network by acquiring North Ridge Pharmacy, bringing its full-service pharmacy count to 54.
Analysis · GRDN · Trade & Services
Guardian Pharmacy Services reported robust financial results for both the fourth quarter and full year 2025, demonstrating significant operational improvements and a strong financial turnaround. The company transitioned from a net loss of $71.0 million in 2024 to a net income of $49.0 million in 2025, driven by substantial revenue and Adjusted EBITDA growth. This positive performance is further underscored by a raised Adjusted EBITDA guidance for fiscal year 2026, signaling management's increased confidence in future profitability. The healthy balance sheet, with $65.6 million in cash and no long-term debt under its credit facility, provides a solid foundation for continued growth and strategic initiatives, including recent acquisitions.
At the time of this filing, GRDN was trading at $34.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $18.37 to $37.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.